Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder

CNS Spectr. 2021 Jun;26(3):195-196. doi: 10.1017/S1092852920001625. Epub 2020 Jul 9.

Authors

Sean J Pittock¹, Ilene Weitz², James F Howard³, Guido Sabatella⁴, Sunil Mehta⁴, Jeremy Franklin⁴

Affiliations

¹ Mayo Clinic, Rochester, Minnesota, USA.
² Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
³ Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
⁴ Alexion Pharmaceuticals, Boston, Massachusetts, USA.

PMID: 32641193
DOI: 10.1017/S1092852920001625

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Neuromyelitis Optica*
Pharmaceutical Preparations*
Product Labeling
Vaccination

Substances

Antibodies, Monoclonal, Humanized
Pharmaceutical Preparations
eculizumab